Business Wire

AM-PHARMA

Share
400 Patients Have Been Enrolled in AM-Pharma’s Pivotal Phase 3 Study of Ilofotase Alfa for the Treatment of Sepsis-associated Acute Kidney Injury

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that 400 patients have now been enrolled in the main trial population in the pivotal Phase 3 REVIVAL study. The REVIVAL study is evaluating AM-Pharma’s proprietary recombinant alkaline phosphatase, ilofotase alfa, for the treatment of patients with sepsis-associated acute kidney injury (SA-AKI). Per the study protocol, four interim analyses for futility and/or efficacy will be conducted when enrollment hits certain levels and the first futility analysis will occur when 400 patients in the main trial population have been treated and have reached day 28.

The primary endpoint of the study is all-cause mortality 28 days post-treatment start. Once the first 400 patients enrolled in the main study population in the study reach the 28-day primary endpoint, the blinded data will be analyzed and sent to the data monitoring committee (DMC) for review. The DMC will then evaluate for futility based on pre-defined criteria. The company anticipates that the DMC futility decision will be available in July.

“Hitting this first enrollment threshold in REVIVAL is a significant achievement for our company and we look forward to receiving the futility assessment from the DMC,” said Erik van den Berg, Chief Executive Officer of AM-Pharma. “There are three additional futility/efficacy analyses scheduled at the 700, 850 and 1,000 patient thresholds. We see each of these interim analyses as de-risking to the program and, importantly, as potential events that could enable us to stop the study for efficacy and expedite the time to market for ilofotase alfa.”

In the Phase II study of ilofotase alfa, the comparable patient group treated with the 1.6mg/kg dose experienced a statistically significant 46% relative reduction in mortality at day 28 compared to the group treated with placebo (p= 0.022). REVIVAL, the single global pivotal Phase III study of ilofotase alfa in SA-AKI patients, was initiated in November 2020 and is enrolling patients at up to about 120 clinical sites in North America, Europe, Japan, Australia and New Zealand. The U.S. Food and Drug Administration, European Medicines Agency and Japanese Pharmaceuticals and Medical Devices Agency have all approved the REVIVAL protocol.

About REVIVAL

The REVIVAL Phase III pivotal trial is a randomized, double-blind, placebo-controlled, two-arm, parallel-group, multi-center trial to evaluate the efficacy and safety of AM-Pharma’s proprietary human recombinant alkaline phosphatase, ilofotase alfa, for the treatment of patients with SA-AKI. The study will enroll approximately 1400 patients with SA-AKI in the main study population. In two exploratory cohorts, up to 100 patients with moderate Chronic Kidney Disease (CKD) and up to 100 patients with COVID-19 will also be enrolled. Patients in the study will be randomized to receive 1.6mg/kg of ilofotase alfa or placebo. The primary aim of the study is to confirm the improvement on the primary endpoint of 28-day all-cause mortality, as observed in the Phase II STOP-AKI study. Secondary endpoints include the treatment effect on long-term Major Adverse Kidney Events (MAKE), on the use of organ support, length of stay in the ICU and on 90-day all-cause mortality. Further information on this study can be found at www.clinicaltrials.gov , NCT04411472 (REVIVAL).

About Ilofotase Alfa

Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that in multiple clinical trials was shown to be stable and highly active. The recombinant enzyme displays exquisite activity towards dephosphorylating and detoxifying damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS), ATP, ADP and other extracellular substrates that drive acute inflammation, coagulation and microvascular ischemia found in kidney following sepsis or ischemia-induced damage. Research has shown that ATP dephosphorylation has a double effect in protecting against kidney injury. When the pro-inflammatory ATP is dephosphorylated, the resulting adenosine further reduces inflammation through the activation of the immunosuppressive adenosine A2a receptor pathway.

About AM-Pharma

AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year. Our proprietary compound, ilofotase alfa, has the potential to become the first treatment for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals. Find out more about us online at: www.am-pharma.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Veracode Named a Leader in the Gartner® Magic Quadrant™ Application Security Testing for 11th Consecutive Time14.10.2025 17:48:00 CEST | Press release

Company Recognized for its Ability to Execute and Completeness of Vision Veracode, the global leader in application risk management, has once again been positioned as a Leader in the 2025 Gartner® Magic Quadrant™ for Application Security Testing (AST)¹. This marks the company’s 11th consecutive time as a Leader since the report was first published. The analysis represents one of the industry’s most in-depth and unbiased evaluations of market competitors. “Over nearly two decades, Veracode has earned a reputation as a trusted partner for thousands of organizations worldwide,” said Derek Maki, Senior Vice President & Head of Product at Veracode. “From pioneering security integration into the software development lifecycle to redefining AI-powered application risk management, we’ve always been at the forefront of innovation. We believe our continued position as a Leader in the Gartner Magic Quadrant reflects our unwavering commitment to customer success and the meaningful impact we delive

From the Court to Commerce: Tennis Champion Rafael Nadal to Headline VTEX Connect Europe 202514.10.2025 17:08:00 CEST | Press release

November 11 marks the evening global commerce, AI, and enterprise excellence converge, complementing Web Summit Global Conference Week 2025 in Lisbon. VTEX (NYSE: VTEX), the sole Customers’ Choice commerce platform for two years by Gartner® and trusted by global brands including Colgate, Stanley Black & Decker, and Whirlpool, announces that 22-time Grand Slam tennis champion and entrepreneur Rafael Nadal, will headline VTEX Connect Europe on November 11, 2025, at Pavilhão Carlos Lopes in Lisbon, Portugal. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014941918/en/ Held alongside Web Summit 2025, the world’s largest technology gathering, VTEX Connect Europe on November 11 has become the premier evening for global digital commerce to unite. The event will bring together thousands from retail, manufacturing, and technology to uncover ways enterprise digital commerce and AI has transformed operations, customer experience, an

Hyper Unveils HyperSpace Trackpad Pro: First Premium Haptic Trackpad for Microsoft Windows14.10.2025 16:15:00 CEST | Press release

This zero-latency, force-sensing trackpad with intelligent shortcuts and ergonomic design is purpose-built to elevate users’ productivity and creative workflows Hyper®, the creator of innovative tech accessories for creators and power users, today announced the Kickstarter launch of its groundbreaking HyperSpace™ Trackpad Pro, the industry’s most advanced trackpad designed specifically for Microsoft® Windows® users. This next-generation trackpad features advanced piezo haptics, full-force sensing technology, and deep personalization experience, transforming how users interact with their productivity and creative apps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013986927/en/ The world’s most advanced Windows® trackpad. HyperSpace Trackpad Pro delivers precision, contextual haptics, and full-force sensing. “With approximately 70 percent of desktops and laptops running Windows, users have long-awaited a premium external

WeWork Companies LLC Commends Franchisee WeWork India on IPO and Public Listing14.10.2025 16:00:00 CEST | Press release

Milestone underscores strength of the WeWork global brand and WeWork India’s position as the country’s leading flexible office space provider WeWork Companies LLC (WeWork), the privately held parent company of its franchisee WeWork India Management Limited (“WeWork India”), applauds and fully supports the launch of their IPO and listing on the National Stock Exchange of India. The entities have enjoyed a long and positive partnership since WeWork India’s founding in 2017, during which time it has grown to become the top flexible office space provider in the country. “WeWork India is shaping the future of work in India,” said John Santora, Chief Executive Officer of WeWork. “The listing marks an important moment for the country’s flexible workspace sector, underscoring both market confidence and growing demand for dynamic office solutions in the region. We have been a proud partner of WeWork India and have witnessed their rise as the clear leader in the space in which they operate.” “Ov

LevelBlue to Acquire Cybereason, Expanding Global Leadership in Managed Detection and Response, XDR, Incident Response, and Threat Intelligence14.10.2025 16:00:00 CEST | Press release

Acquisition Strengthens LevelBlue’s Position as the World’s Largest Pure-Play MSSP; Adds Investment from SoftBank Corp., SoftBank Vision Fund 2, and Liberty Strategic Capital LevelBlue, the world’s largest pure-play provider of managed security services, today announced it has signed a definitive agreement to acquire Cybereason, a leading cybersecurity firm known for its advanced Extended Detection and Response (XDR) platform, elite threat intelligence team, and digital forensics and incident response (DFIR) capabilities. For clients and strategic partners, the acquisition delivers immediate value with stronger threat detection, faster response, and broader global coverage, all from a single, unified security partner. By combining LevelBlue’s AI-powered capabilities and industry-leading MDR offerings with Cybereason’s deep expertise, organizations can better address today’s complex cyber challenges while reducing operational complexity and risk. “The addition of Cybereason is a strateg

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye